From Inquiry to Randomization: Reading a Trial Screening Flowchart

A clinical trial's most familiar number is often the number randomized. Yet the pathway leading to that number may be just as important for understanding the evidence. People can inquire, complete an initial screen, undergo a detailed assessment, decline further participation, or be excluded before assignment. Each step answers a different question about feasibility, selection, and applicability.

In MDMA PTSD research, readers should not turn a screening description into a self-assessment tool. Eligibility decisions belong to authorized study teams using the actual protocol and clinical information. The purpose here is to understand the evidence pipeline, not to tell anyone how to qualify, what to disclose, or whether an investigational intervention is suitable for them.

Label each stage precisely

An inquiry is not an enrollment. A person contacting a study may never provide enough information to determine eligibility. Prescreening can reduce the burden of a lengthy assessment, but its results may be based on a limited set of questions. A more detailed screening process can produce a different decision without either stage being inherently inconsistent.

Randomization usually marks entry into the assigned comparison. The 2023 phase 3 publication reports 104 randomized participants. That figure should not be described as everyone who initially sought participation. A clear flowchart keeps the stages separate and gives readers a way to trace which denominator belongs to a particular result.

Exclusion reasons have different meanings

A person may fail a protocol criterion for a clinical reason, lack the practical ability to attend visits, or decide that participation does not fit their preferences. Combining those reasons into a single rejected category obscures meaningful differences. It can also encourage the false impression that every person who did not enroll was medically unsuitable.

Some exclusions are designed to reduce foreseeable risk. Others help define a study population or limit confounding. Readers should not assume that a research criterion is a general clinical prohibition or a universal rule across future studies. Our recruitment and representation article explains how selection affects generalizability beyond individual eligibility decisions.

Do not infer prevalence from a screened sample

People approaching a specialized trial are not a random sample of everyone with PTSD. They may have different treatment histories, expectations, resources, or willingness to consider experimental care. If many screened volunteers have a certain characteristic, that does not establish how common it is in the broader PTSD population.

Similarly, a high screening exclusion rate does not by itself prove that an intervention is unsafe for most people. It shows that the recruitment pool and protocol did not align for many candidates. Understanding why requires specific exclusion data and the context of recruitment. A percentage without that context invites interpretations the flowchart cannot support.

Keep correction notices in the evidence trail

The FDA issued an erratum to its June 2024 briefing document. Among other corrections, it addressed wording concerning additional MAPP2 exclusion criteria. This is a practical reminder that quoting an official document is not enough if a related correction changes the passage being cited.

When describing criteria, compare the study report, protocol where available, and corrected regulatory materials. If they appear inconsistent, report the uncertainty rather than resolving it through guesswork. Official documents can have different purposes or use different summaries, and a correction should travel with the claim it changes.

Follow participants after assignment as well

A recruitment flowchart should lead into a retention account. Readers need to know how many assigned participants received the intervention, completed assessments, discontinued treatment, or remained available for follow-up. These categories are not interchangeable. Someone can stop an intervention yet still provide outcome data, which may remain important to the randomized analysis.

Our evidence workbook describes why missing observations create analytical assumptions. A clean-looking final sample can be misleading if it hides departures that differed between groups. Transparent flow reporting helps readers judge that problem without requiring them to assume every departure had the same cause.

What a prospective participant can reasonably ask

A study team can explain the major stages of screening, the expected time commitment, what information is collected, and whether participation may end before randomization. NIMH participant information supports understanding research as a voluntary process with uncertain benefit. An assessment appointment should not be portrayed as a promise of access or a guarantee of treatment.

People should also understand privacy arrangements and what happens to screening information if they do not enroll. They may wish to ask whether a clinical concern identified during assessment will be communicated and how ordinary care should continue. Those questions concern process and continuity, not strategies for bypassing safeguards.

Use flow data to improve the next study

Good reporting can reveal avoidable barriers, such as recruitment messages that attract people unlikely to meet key criteria or scheduling that excludes otherwise eligible volunteers. It can also identify where a study needs a different population or additional safety research. The aim is not to make every person eligible but to make selection scientifically justified and ethically transparent.

For readers, the main discipline is simple: name the stage, name the denominator, and keep the reason visible. That approach makes recruitment claims more accurate and prevents a small randomized sample from being mistaken for an unfiltered picture of everyone seeking help for PTSD.

Status and scope: Editorial cutoff: October 30, 2026. MDMA-assisted therapy is discussed here as investigational in the United States. The sources cited do not establish FDA approval; a submission, meeting, or prediction is not an approval. This article provides research education, not treatment instructions or individualized medical advice.

Sources

• Mitchell et al. (2023), MDMA-assisted therapy for moderate to severe PTSD; updated article including correction
• FDA (June 2024), midomafetamine advisory committee briefing document
• FDA (June 2024), briefing document erratum
• NIMH, Clinical Trials—Information for Participants

Disclosure: Consult a qualified health professional for decisions about symptoms or care.

Editorial disclosure: Generated pictures are illustrative, not study participants. Consult a qualified professional for personal care.